Introduction
============

Contrast-induced nephropathy (CIN) is one of the major causes of acute kidney injury (AKI) in hospitalized patients. The mechanism of this injury is multifactorial;[@b1-ijnrd-11-211] osmolality or the type of contrast media used may play a role in developing CIN.[@b2-ijnrd-11-211],[@b3-ijnrd-11-211] Risk factors for CIN include abnormal kidney function at baseline[@b4-ijnrd-11-211] and diabetes. In addition, the use of certain drugs such as angiotensin converting enzyme inhibitors or diuretics may increase the risk for CIN.[@b5-ijnrd-11-211] A number of tests have been proposed to predict CIN, including hemoglobin,[@b6-ijnrd-11-211] serum albumin,[@b7-ijnrd-11-211] and alkaline phosphatase.[@b8-ijnrd-11-211]

Cytokines of innate immunity have been proposed to predict coronary artery disease (CAD) in patients with already established disease[@b9-ijnrd-11-211] or in healthy subjects,[@b10-ijnrd-11-211] as a marker of active inflammatory processes. Plasma neutrophil gelatinase-associated lipocalin (NGAL), which is a new biomarker used to identify patients at risk for AKI, was shown to be elevated in patients with CAD and heart failure.[@b11-ijnrd-11-211] In patients with atherosclerosis, CAD manifested as elevated cytokine levels may predispose to worse renal outcome after cardiac catheterization.[@b12-ijnrd-11-211] The aim of this study is to evaluate the possible role of inflammatory milieu, manifested by high C-reactive protein (CRP), multiple cytokines (interleukin \[IL\]-1α, IL-6, IL-19, IL-20, IL-21, IL-22, and IL-33), and NGAL levels, in increased risk for CIN.

Patients and methods
====================

Study population
----------------

An informed consent was obtained from all our participating patients. The study protocol was approved by the ethics committee and the Institutional Review Board at King Abdullah University Hospital, Jordan, and has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Using prospective observational design, between June 2015 and January 2016, we approached and evaluated 1,810 patients admitted to the cardiology ward in a tertiary referral hospital for cardiac catheterization (indications included acute coronary syndrome such as unstable angina, non-ST elevation myocardial infarction, ST-elevation myocardial infarction), who only used low-osmolality contrast media (CM) (Lopamidol, Bayer, Germany). Patients with stage 4, 5 renal failure, patients on dialysis, and patients with recent intravenous contrast use, active infection, or any type of cancers were excluded from the study. After applying the inclusion and exclusion criteria, 326 patients agreed and signed the consent to participate in the study.

Study protocol and definitions
------------------------------

All patients were assessed and evaluated at admission. Vital signs were recorded at admission and at the time of the procedure. Data regarding patients' demographics, comorbidities, and medication history were collected from the patients at the time of admission. Laboratory tests including complete blood count, kidney function, liver function, random blood sugar, HbA1c, uric acid, alkaline phosphatase, thyroid function, parathyroid hormone, 1,25 dihydroxyvitamin D3, and urine analysis were performed. Lipid profile was done at the time of admission if patients had been fasting for at least 12 hours; otherwise, it was done the next morning. Renal function was assessed using estimated glomerular filtration rate which was calculated using the Modification of Diet in Renal Disease equation.[@b13-ijnrd-11-211],[@b14-ijnrd-11-211] Echocardiography to measure left ventricular ejection fraction was done within 1 week of the procedure. The choice of renal protective measures was left to the treating cardiology team.

Patients had blood withdrawn 48 hours after the procedure for their creatinine level. CIN was defined as an increase in serum creatinine by \>25% or 44 μmol/L from the baseline level (48--72) hours after contrast administration, without any other obvious cause.[@b15-ijnrd-11-211] Based on the lab cutoff, patients with vitamin D below 20 ng/mL were considered to be vitamin D deficient. Previous contrast use was defined as intravenous contrast administration within 1 week before the admission. Of the initial 326 patients included, 202 patients had their second sample taken and, thus, were eligible to continue in the study.

Cytokine measurements
---------------------

At the time of procedure, serum was taken for CRP analysis using qualitative and semi-quantitative latex method (Linear, Montgat, Spain). The titer is expressed as the reciprocal of the highest dilution showing macroscopic agglutination, with the normal levels for adults being \<6 mg/L. The procedure for CRP measurements was conducted in accordance with the manufacturer's datasheet.

Remaining serum was frozen in aliquots at −80°C until further work was performed. The cytokine NGAL level was measured after dilution to 1:20, and other cytokines (IL-1α, IL-6, IL-19, IL-20, IL-21, IL-22, and IL-33) were measured directly without dilution of the sample according to the manufacturers' instructions. Cytokines' levels in serum were determined using enzyme-linked immunosorbent assay. Procedures of each cytokine immunoassay, including reagent and standard preparations, were conducted following instructions in the manufacturers' datasheets. OD of each sample was determined using enzyme-linked immunosorbent assay reader at 450 nm wavelength. The manufacturer information is as follows: IL-1α (R&D Systems, Inc., Minneapolis, MN, USA), IL-6 (R&D Systems), IL-19 (R&D Systems), IL-20 (R&D Systems), IL-21 (eBiosience, San Diego, CA, USA), IL-22 (R&D Systems), IL-33 (R&D Systems), and NGAL (RayBio, Norcross, GA, USA).

Statistical analysis
--------------------

All analyses were performed using SPSS (version 20; IBM Corporation, Armonk, NY, USA). Data were described using means and SD for continuous variables and percentages for categorical variables. For the purpose of the study, patients were divided into two groups: patients with CIN and patients without CIN. An independent-samples *t*-test was performed to compare the means of continuous variables in the two groups. A chi-squared test of independence was performed to examine the relation between the incidence rates of CIN (with and without CIN) according to the demographic, clinical, and other relevant characteristics of the participants. Multivariate binary logistic regression was conducted to measure and determine the influence of factors associated with CIN. A *P*-value \<0.05 was considered statistically significant.

Results
=======

Patients' characteristics
-------------------------

Patients (N=202, 28.2% females and 71.8% males) were enrolled in the study, and were examined at admission and after 48 hours of the procedure. Their age ranged between 29 and 87 years, with a mean±SD of 55.8±9.7 years. The demographic and clinical characteristics of the participants are shown in [Table 1](#t1-ijnrd-11-211){ref-type="table"}. About two-thirds (68.8%) of patients had hypertension and almost half of them (47.0%) had CAD.

Incidence of CIN
----------------

Approximately 14.8% (n=30) of the patients developed CIN. The incidence rate was 21.1% among females and 12.4% among males. [Table 2](#t2-ijnrd-11-211){ref-type="table"} shows the incidence rate of CIN according to demographic, clinical, and relevant characteristics of the participants. The incidence rate did not differ significantly according to the studied variables, except for use of diuretics. The incidence rate was significantly higher among patients who were on diuretics compared to those who were not on diuretics (21.3% vs 11.0%, *P*=0.047). As per the cardiologist's decision, 10.9% of patients received hydration as a therapy for CIN.

Factors associated with CIN
===========================

We evaluated the role of inflammatory biomarkers (CRP, IL-1α, IL-6, IL-19, IL-20, IL-21, IL-22, IL-33, NGAL) and the incidence of CIN.

The levels of different biomarkers are shown in [Table 3](#t3-ijnrd-11-211){ref-type="table"}. In univariate analysis, IL-33 and NGAL showed significant impact on CIN. Patients with CIN had a significantly lower mean creatinine level on admission (73.3 μmol/L for CIN vs 87.6 μmol/L, *P*=0.01), higher estimated glomerular filtration rate, and lower parathyroid hormone (PTH) level, compared to those who did not develop CIN. In multivariate analysis, IL-33 was a statistically significant predictor of CIN (*P*=0.001). For each unit increase in IL-33, the odds of CIN increased by 1.4 times. On the other hand, CRP was not a statistically significant predictor of CIN. There was no significant difference between patients with CIN and those who did not develop CIN in terms of the contrast amount used (99.8 mL for the CIN group vs 99.2 mL for the no CIN group, *P*=0.95).

Discussion
==========

Serum creatinine is a poor marker for the evaluation and prediction of CIN as it takes time to increase and to be detected clinically.[@b16-ijnrd-11-211] In the current study, IL-33 was identified as a possible predictive biomarker for increased risk of CIN.

Patients with cardiac disease usually have an inflammatory process, which can lead to atherosclerosis and CAD.[@b17-ijnrd-11-211],[@b18-ijnrd-11-211] A number of biomarkers have been proposed to evaluate inflammation, such as CRP.[@b19-ijnrd-11-211] Though CRP was found to be an important marker for prognosis in cardiac disease, it was not a good predictor of CIN as indicated by current results.

Kidneys, in an inflammatory milieu, can be predisposed to more risk of injury,[@b20-ijnrd-11-211] especially after CIN.[@b12-ijnrd-11-211] In the current study, elevation of IL-33 was found to be associated with CIN. Other cytokines and inflammatory biomarkers including IL-1α, IL-6, IL-19, IL-20, IL-21, IL-22, IL-33, and NGAL were not found to predict CIN. Some of the former mentioned cytokines that were evaluated in cardiac diseases, including IL-1, IL-6, and IL-19--22,[@b10-ijnrd-11-211],[@b21-ijnrd-11-211]--[@b23-ijnrd-11-211] were found to have a potential role in predicting CIN.[@b21-ijnrd-11-211],[@b24-ijnrd-11-211] However, as indicated by the current results, they are not good predictors for CIN.

IL-33 is a new IL-1 family member that was presented as an important molecule that invites the inflammatory cells to the kidney in cisplatin-induced nephropathy.[@b25-ijnrd-11-211] It was found to be associated with the pathogenesis of various disorders, including autoimmune diseases, myocardial infarction, heart failure, and allergic pulmonary diseases.[@b26-ijnrd-11-211] IL-33 is modulated by necrosis and apoptosis, which are the major features of CIN.[@b27-ijnrd-11-211] Current results suggest an important role for IL-33 in the course of CIN. Prevention of inflammation mediated by molecules such as IL-33 may represent the key target for preventing CIN.

The exact pathophysiologic mechanisms of CIN are not fully understood; however, inflammation, hypoxia, and oxidative stress constitute the main responsible pathways, especially in diabetic kidney disease (DKD).[@b27-ijnrd-11-211] A previous study showed increased IL-33 levels in the kidney tissues and serum of diaetic rats with CIN. Thus, a role for IL-33 in the pathogenesis of CIN has been proposed.[@b27-ijnrd-11-211] IL-33 is released from the necrotic cells, binds the interleukin 1 receptor on immune cells, and increases the secretion of cytokines, with resultant inflammation.[@b28-ijnrd-11-211],[@b29-ijnrd-11-211] Expression of IL-33 was typically located in the peritubular and intraglomerular capillaries of diabetic mice. The release of IL-33 from necrotic cells could induce autophagy, which can further balance the effects of increased apoptosis secondary to CIN in DKD.[@b30-ijnrd-11-211],[@b31-ijnrd-11-211]

Conducting further analysis of IL-33 levels at time points earlier than 48 hours following CIN is suggested, which could spare the time to wait for serum creatinine to rise. Additionally, conducting a multicenter trial would be great to show replication of these observations.

Conclusion
==========

Current results showed that serum level of IL-33 is a predictor for AKI after CIN. Thus, good clinical judgment and high serum level of IL-33 may be used to stratify patients into low and high risk for CIN.
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###### 

Demographic, clinical, and relevant characteristics of the participants

                             n            \%
  -------------------------- ------------ ------
  Age, mean (SD)             55.8 (9.7)   
  Gender                                  
   Female                    57           28.2
   Male                      145          71.8
  Smoking                                 
   No                        92           45.8
   Current                   79           39.3
   Past                      30           14.9
  Diabetes mellitus          88           43.6
  Hypertension               139          68.8
  Congestive heart failure   54           26.9
  Cerebrovascular accident   21           10.4
  Coronary artery disease    95           47.0

###### 

The incidence rate of contrast-induced nephropathy according to demographic, clinical, and relevant characteristics of the participants

                                            Contrast-induced nephropathy   *P*-value               
  ----------------------------------------- ------------------------------ ----------- ---- ------ -------
  Gender                                                                                           0.120
  Female                                    45                             78.9        12   21.1   
  Male                                      127                            87.6        18   12.4   
  Smoking                                                                                          0.233
  No                                        74                             80.4        18   19.6   
  Current                                   70                             88.6        9    11.4   
  Past                                      27                             90.0        3    10.0   
  Diabetes mellitus                                                                                0.978
  No                                        97                             85.1        17   14.9   
  Yes                                       75                             85.2        13   14.8   
  Hypertension                                                                                     0.562
  No                                        55                             87.3        8    12.7   
  Yes                                       117                            84.2        22   15.8   
  congestive heart failure                                                                         0.979
  No                                        125                            85.0        22   15.0   
  Yes                                       46                             85.2        8    14.8   
  Cerebrovascular accident                                                                         0.568
  No                                        155                            85.6        26   14.4   
  Yes                                       17                             81.0        4    19.0   
  Coronary artery disease                                                                          0.103
  No                                        87                             81.3        20   18.7   
  Yes                                       85                             89.5        10   10.5   
  Angiotensin converting enzyme inhibitor                                                          0.309
  No                                        114                            87.0        17   13.0   
  Yes                                       58                             81.7        13   18.3   
  Angiotensin receptor blockers                                                                    0.306
  No                                        135                            86.5        21   13.5   
  Yes                                       37                             80.4        9    19.6   
  Diuretics                                                                                        0.047
  No                                        113                            89.0        14   11.0   
  Yes                                       59                             78.7        16   21.3   
  Nonsteroidal anti-inflammatory drugs                                                             0.313
  No                                        157                            84.4        29   15.6   
  Yes                                       15                             93.8        1    6.3    
  Statin                                                                                           0.980
  No                                        52                             85.2        9    14.8   
  Yes                                       120                            85.1        21   14.9   
  Pre-procedure hydration                                                                          0.568
  No                                        155                            85.6        26   14.4   
  Yes                                       17                             81.0        4    19.0   
  eGFR, mL/min \<60                         25                             86.2        4    13.8   0.863
  ≥+60                                      147                            85.0        26   15.0   

**Abbreviation:** eGFR, estimated glomerular filtration rate.

###### 

CRP and interleukins based on CIN status

  Variable                  CIN (+)       CIN (−)
  ------------------------- ------------- -------------
  CRP mg/L, mean (±SD)      8.3 (12.9)    11.5 (37.9)
  IL-1α ng/mL, mean (±SD)   2.1 (2.7)     2.4 (3.2)
  IL-6 ng/mL, mean (±SD)    2.7 (2.4)     3.1 (2.8)
  IL-19 ng/mL, mean (±SD)   5.8 (8.2)     9.5 (11.3)
  IL-20 ng/mL, mean (±SD)   2.9 (4.0)     2.1 (3.3)
  IL-21 ng/mL, mean (±SD)   29.7 (20.0)   40.2 (36.6)
  IL-22 ng/mL, mean (±SD)   4.7 (5.9)     5.9 (8.6)
  IL-33 ng/mL, mean (±SD)   2.2 (2.2)     1.0 (1.5)
  NGAL ng/mL, mean (±SD)    10.5 (10.3)   16.6 (15.2)

**Abbreviations:** CIN, contrast-induced nephropathy; CRP, C-reactive protein; NGAL, neutrophil gelatinase-associated lipocalin.
